Your browser doesn't support javascript.
loading
Severe disease during both primary and secondary dengue virus infections in pediatric populations.
Aggarwal, Charu; Ahmed, Hasan; Sharma, Pragati; Reddy, Elluri Seetharami; Nayak, Kaustuv; Singla, Mohit; Maheshwari, Deepti; Chawla, Yadya M; Panda, Harekrushna; Rai, Ramesh Chandra; Gunisetty, Sivaram; Priyamvada, Lalita; Bhaumik, Siddhartha Kumar; Ahamed, Syed Fazil; Vivek, Rosario; Bhatnagar, Priya; Singh, Prabhat; Kaur, Manpreet; Dixit, Kritika; Kumar, Sanjeev; Gottimukkala, Kamal; Saini, Keshav; Bajpai, Prashant; Sreekanth, Gopinathan Pillai; Mammen, Shobha; Rajan, Anand; Verghese, Valsan Philip; Abraham, Asha Mary; Shah, Paresh; Alagarasu, Kalichamy; Yu, Tianwei; Davis, Carl W; Wrammert, Jens; Ansari, Aftab; Antia, Rustom; Kabra, Sushil Kumar; Medigeshi, Guruprasad R; Ahmed, Rafi; Lodha, Rakesh; Shet, Anita; Chandele, Anmol; Murali-Krishna, Kaja.
Afiliación
  • Aggarwal C; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Ahmed H; Department of Biology, Emory University, Atlanta, GA, USA.
  • Sharma P; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Reddy ES; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Nayak K; Kusuma School of Biological Sciences, Indian Institute of Technology, New Delhi, India.
  • Singla M; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Maheshwari D; Division of Pediatric Pulmonology and Intensive Care, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
  • Chawla YM; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Panda H; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Rai RC; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Gunisetty S; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Priyamvada L; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Bhaumik SK; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, GA, USA.
  • Ahamed SF; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, GA, USA.
  • Vivek R; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, GA, USA.
  • Bhatnagar P; Division of Infectious Diseases, St. John's Research Institute, St. John's National Academy of Health Sciences, Bengaluru, India.
  • Singh P; Division of Infectious Diseases, St. John's Research Institute, St. John's National Academy of Health Sciences, Bengaluru, India.
  • Kaur M; The University of Trans-Disciplinary Health Sciences & Technology, Bengaluru, India.
  • Dixit K; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Kumar S; TERI school of advanced studies, New Delhi, India.
  • Gottimukkala K; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Saini K; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Bajpai P; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Sreekanth GP; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Mammen S; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Rajan A; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Verghese VP; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Abraham AM; ICGEB Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Shah P; Department of Clinical Virology, Christian Medical College, Vellore, India.
  • Alagarasu K; Department of Clinical Virology, Christian Medical College, Vellore, India.
  • Yu T; Pediatric Infectious Diseases, Department of Pediatrics, Christian Medical College, Vellore, India.
  • Davis CW; Department of Clinical Virology, Christian Medical College, Vellore, India.
  • Wrammert J; Department of Molecular Virology, National Institute of Virology, Pune, India.
  • Ansari A; Department of Molecular Virology, National Institute of Virology, Pune, India.
  • Antia R; Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  • Kabra SK; Shenzhen Research Institute of Big Data, School of Data Science, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
  • Medigeshi GR; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Ahmed R; Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, GA, USA.
  • Lodha R; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Shet A; Department of Biology, Emory University, Atlanta, GA, USA.
  • Chandele A; Division of Pediatric Pulmonology and Intensive Care, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
  • Murali-Krishna K; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Nat Med ; 30(3): 670-674, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38321219
ABSTRACT
Dengue is a global epidemic causing over 100 million cases annually. The clinical symptoms range from mild fever to severe hemorrhage and shock, including some fatalities. The current paradigm is that these severe dengue cases occur mostly during secondary infections due to antibody-dependent enhancement after infection with a different dengue virus serotype. India has the highest dengue burden worldwide, but little is known about disease severity and its association with primary and secondary dengue infections. To address this issue, we examined 619 children with febrile dengue-confirmed infection from three hospitals in different regions of India. We classified primary and secondary infections based on IgMIgG ratios using a dengue-specific enzyme-linked immunosorbent assay according to the World Health Organization guidelines. We found that primary dengue infections accounted for more than half of total clinical cases (344 of 619), severe dengue cases (112 of 202) and fatalities (5 of 7). Consistent with the classification based on binding antibody data, dengue neutralizing antibody titers were also significantly lower in primary infections compared to secondary infections (P ≤ 0.0001). Our findings question the currently widely held belief that severe dengue is associated predominantly with secondary infections and emphasizes the importance of developing vaccines or treatments to protect dengue-naive populations.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dengue Grave / Dengue / Virus del Dengue / Coinfección Tipo de estudio: Guideline Límite: Child / Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dengue Grave / Dengue / Virus del Dengue / Coinfección Tipo de estudio: Guideline Límite: Child / Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos